Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study To Evaluate The Single Dose Pharmacokinetics Of Dacomitinib (PF-00299804) In Subjects With Impaired Hepatic Function

Next Previous
X
Search
Trial Profile

A Phase 1 Study To Evaluate The Single Dose Pharmacokinetics Of Dacomitinib (PF-00299804) In Subjects With Impaired Hepatic Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dacomitinib (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Pharmacokinetics
  • Sponsors Pfizer

    • Most Recent Events

    • 23 Feb 2022 Results assessing the effect of hepatic impairment on the pharmacokinetics of dacomitinib, two dedicated studies (NCT01571388 and NCT03865446) conducted to inform optimal dosing, published in the Clinical Drug Investigation.
    • 25 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top